In a GBM mouse model, VEGFR blockage with the administration of Sunitinib (Sutent) and the VEGF inhibitor Bevacizumab (Avastin) prolonged survival, reduced myeloid infiltrates, and decreased tumor vascularity [39]. Here, KDR is linked to glioblastoma.